Mioara Larion, Ph.D.
Building 37, Roon 1136A Bethesda, MD 20892
The overarching goal and drivers behind Dr. Larion’s research are to eventually observe the direct impact that cancer metabolomics can have on patient diagnosis, treatment and survival.
Since IDH mutations cause metabolic reprogramming, Dr. Larion’s research focuses on how this can be exploited for therapeutic development or imaging studies that aid earlier diagnosis of progression. Dr. Larion’s laboratory has identified that lipid pathways are important for IDH1-mutant glioma growth and targeting specific enzymes from either fatty acid synthesis or sphingolipid pathway leads to specific cellular death in these cells (see figure).
Intracellular proteins, lipids and nucleic acids can be quantified at the cellular and organelle level using Raman spectroscopy, which has been a significant contributing technology to this project. Capturing changes in these molecules has allowed a deeper understanding of the intrinsic vulnerabilities of IDH-mutant glioma cells and studying this disease from various angles which may result in better diagnostic, surgical and therapeutic benefits for patients. Dr. Larion hopes that her research will eventually lead to the creation of a “metabolomic map” for each patient outlining their nutrient availability, mutational profile, and metabolomic dependency possibly segregated by organelles using Raman spectroscopy.
Dr. Larion is originally trained as a biochemist and biophysicist during both her Bachelor of Science degree in Romania, and her Master of Science and Ph.D. degree from the Department of Chemistry and Biochemistry at Florida State University. Her work during graduate school involved biophysics and enzymology. During this time, Dr. Larion developed a passion for learning enzymes function and how this can cause or exacerbate certain disease states. Shortly thereafter, she joined the Neuro-Oncology Branch at NIH as an Investigator and was introduced to the field of oncology, where she now leads the Cancer Metabolism Program.
Dr. Larion is also involved in a number of committees outside her research including serving as the Co-Chair of the first NCI-SNO Joint Symposium on Targeting CNS Tumor Metabolism, the Visiting Scholars Program at the Neuro-Oncology Branch, participating in NIH Grant Review Panels for metabolomics-related research, and organizer of the Metabolomics Association of North America Conference.
Honors, Awards and Leadership
- Organizer, 1st Metabolomics Association of North America - 2019
- 2018-2020 Performance Award
- Member of the “Precision Medicine Task Force”, Metabolomics Society – 2018 to present
- Member, NIH Review Panel for Metabolomics ZRG1 BST-X (50) – 2016
- Co-Chair, Visiting Scholars Program for Neuro-Oncology Branch – 2016 to present
- Co-Chair, 1st NCI-SNO Symposium on Targeting CNS Tumor Metabolism – 2020
- Chair of the NIH Cancer Metabolism Interest Group – 2021 to present
Select Societies and Initiatives
- American Association for Cancer Research (AACR)
- Society of Neuro-Oncology (SNO)
- Biophysical Society
Whittington AC, Larion M, Bowler JM, Ramsey KM, Brüschweiler R, Miller BG. Dual allosteric activation mechanisms in monomeric human glucokinase. Proc Natl Acad Sci U S A. 2015;112(37):11553-8.
Larion M, Hansen AL, Zhang F, Bruschweiler-Li L, Tugarinov V, Miller BG, Brüschweiler R. Kinetic Cooperativity in Human Pancreatic Glucokinase Originates from Millisecond Dynamics of the Small Domain. Angew Chem Int Ed Engl. 2015;54(28):8129-32.
Larion M, Salinas RK, Bruschweiler-Li L, Miller BG, Brüschweiler R. Order-disorder transitions govern kinetic cooperativity and allostery of monomeric human glucokinase. PLoS Biol. 2012;10(12):e1001452.
Larion M, Salinas RK, Bruschweiler-Li L, Brüschweiler R, Miller BG. Direct evidence of conformational heterogeneity in human pancreatic glucokinase from high-resolution nuclear magnetic resonance. Biochemistry. 2010;49(37):7969-71.
Related Scientific Focus Areas
Molecular Biology and Biochemistry
This page was last updated on September 3rd, 2021